Vitamin B12 Status of Patients Treated With Metformin: A Cross-Sectional Cohort Study
Leif Sparre Hermann; Bo Nilsson; Staffan Wettre

Abstract
Aim: To assess the vitamin B12 status of patients with type 2 diabetes who had been receiving metformin treatment for at least one year.
Methods: Patients with type 2 diabetes attending a diabetes clinic were included in a cross-sectional cohort study. Patients exposed to metformin for more than one year (n=53) were compared with a non-exposed control group (n=31). Serum cobalamin and other variables reflecting vitamin B12 status were measured.
Results: Patients on metformin had lower cobalamin (289±137 vs. 395±162 pmol/L; p<0.01) and holotranscobalamin (76±49 vs. 97±41 pmol/L; p<0.05), and higher HCy (11.3±3.3 vs. 10.3±2.3 µmol/L; p<0.05); these changes were correlated. Eight metformin patients, but no controls, had holotranscobalamin below the normal range (p<0.05). Methylmalonic acid and folate were similar in both groups.

Conclusion: Patients exposed to long-term metformin therapy had 26.7% lower cobalamin, 21.6% lower holotranscobalamin and 9.7% higher HCy serum concentrations than control subjects. Such changes indicate a potential risk for development of vitamin B12 deficiency. Our results highlight the necessity of checking B12 status during metformin therapy.
 

« Back to abstracts

News

Coming Soon !  The full video recording of the Euromedlab 2007 Active B12 workshop will be available in the next few weeks, register for your copy.

Live CME Web Conference on vitamin B12 deficiency, Prof. Ralph Green, Dec 13th 2007, register now.

read more »

Meetings

8-11 December, 2007
American Society of Hematology, Atlanta, booth 544
read more »